CDIB BioScience Ventures
18
34M
15
0.82
1
0.17
10
- Stages of investment
- Areas of investment
Summary
In 2001 was created CDIB BioScience Ventures, which is appeared as VC. The company was established in North America in United States. The main office of represented VC is situated in the San Diego.
Speaking about the real fund results, this VC is 12 percentage points less often commits exit comparing to other organizations. The increased amount of exits for fund were in 2008. The average startup value when the investment from CDIB BioScience Ventures is 10-50 millions dollars. The important activity for fund was in 2006. Opposing the other organizations, this CDIB BioScience Ventures works on 17 percentage points more the average amount of lead investments. The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 10 - 50 millions dollars.
Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Accelight Networks, Elixir Pharmaceuticals, Epiphany. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Biotechnology, Therapeutics.
The overall number of key employees were 1.
The typical case for the fund is to invest in rounds with 7-8 participants. Despite the CDIB BioScience Ventures, startups are often financed by Venrock, ARCH Venture Partners, Polaris Partners. The meaningful sponsors for the fund in investment in the same round are Venrock, Montreux Equity Partners, Domain Associates. In the next rounds fund is usually obtained by Venrock, MPM Capital, ARCH Venture Partners.
Investments analytics
Analytics
- Total investments
- 18
- Lead investments
- 1
- Exits
- 10
- Rounds per year
- 0.82
- Follow on index
- 0.17
- Investments by industry
- Biotechnology (10)
- Pharmaceutical (8)
- Medical (7)
- Health Care (6)
- Therapeutics (4) Show 18 more
- Investments by region
-
- United States (17)
- Peak activity year
- 2006
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 20
- Avg. valuation at time of investment
- 46M
- Group Appearance index
- 1.00
- Avg. company exit year
- 12
- Avg. multiplicator
- 1.47
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Elixir Pharmaceuticals | 27 Nov 2006 | Biotechnology, Pharmaceutical, Diabetes | Late Stage Venture | 31M | United States, Massachusetts, Cambridge |
| Xanthus Pharmaceuticals | 12 Dec 2003 | Biotechnology, Medical, Pharmaceutical, Biopharma | Early Stage Venture | 30M | United States, Massachusetts, Cambridge |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.